March 30, 2022
argenx announces Annual General Meeting of Shareholders on May 10, 2022
March 29, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving…
Pharmaceuticals, Biotechnology and Life Sciences
March 29, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving…
Received FDA clearance in February 2022 to market Pure-Vu EVS, an all new, next-generation system that has been deployed to…
Total revenue for 2021 was approximately $4.3 millionStrong total cash position of approximately $36.1 million as of December 31, 2021,…
REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting…
Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipelineClinical…
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as…
SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA)…
– Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis – – Unveiled the high-capacity…
NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing…